{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:44:32Z","timestamp":1789609472121,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:00:00Z","timestamp":1495670400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s40259-017-0229-2","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:59:48Z","timestamp":1495673988000},"page":"289-297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-5458","authenticated-orcid":false,"given":"Ian R.","family":"Reid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"key":"229_CR1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF01623352","volume":"4","author":"G Jones","year":"1994","unstructured":"Jones G, Nguyen T, Sambrook PN, et al. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int. 1994;4:277\u201382.","journal-title":"Osteoporos Int"},{"key":"229_CR2","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJM199212033272305","volume":"327","author":"MC Chapuy","year":"1992","unstructured":"Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin-D3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992;327:1637\u201342.","journal-title":"N Engl J Med"},{"key":"229_CR3","doi-asserted-by":"crossref","first-page":"h4580","DOI":"10.1136\/bmj.h4580","volume":"351","author":"MJ Bolland","year":"2015","unstructured":"Bolland MJ, Leung W, Tai V, et al. Calcium intake and risk of fracture: systematic review. BMJ. 2015;351:h4580.","journal-title":"BMJ"},{"key":"229_CR4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women\u2014principal results from the Women\u2019s Health Initiative randomized controlled trial. JAMA. 2002;288:321\u201333.","journal-title":"JAMA"},{"issue":"4","key":"229_CR5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","volume":"177","author":"PJ Snyder","year":"2017","unstructured":"Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Int Med. 2017;177(4):471\u20139.","journal-title":"JAMA Int Med"},{"key":"229_CR6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.2016.21043","volume":"317","author":"MJ Budoff","year":"2017","unstructured":"Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. 2017;317:708\u201316.","journal-title":"JAMA"},{"key":"229_CR7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00198-003-1399-y","volume":"14","author":"PN Biswas","year":"2003","unstructured":"Biswas PN, Wilton LV, Shakir SAW. Pharmacovigilance study of alendronate in England. Osteoporos Int. 2003;14:507\u201314.","journal-title":"Osteoporos Int"},{"key":"229_CR8","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P, et al. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010;95:4380\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"229_CR9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nrendo.2015.71","volume":"11","author":"IR Reid","year":"2015","unstructured":"Reid IR. Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol. 2015;11:418\u201328.","journal-title":"Nat Rev Endocrinol"},{"key":"229_CR10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756\u201365.","journal-title":"N Engl J Med"},{"key":"229_CR11","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s00198-015-3347-z","volume":"26","author":"IR Reid","year":"2015","unstructured":"Reid IR. Denosumab after 8\u00a0years. Osteoporos Int. 2015;26:2759\u201361.","journal-title":"Osteoporos Int"},{"key":"229_CR12","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434\u201341.","journal-title":"N Engl J Med"},{"key":"229_CR13","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/jbmr.1768","volume":"27","author":"EB Andrews","year":"2012","unstructured":"Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012;27:2429\u201337.","journal-title":"J Bone Miner Res"},{"key":"229_CR14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","volume":"107","author":"YQ Gong","year":"2001","unstructured":"Gong YQ, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107:513\u201323.","journal-title":"Cell"},{"key":"229_CR15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/338450","volume":"70","author":"RD Little","year":"2002","unstructured":"Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002;70:11\u20139.","journal-title":"Am J Hum Genet"},{"key":"229_CR16","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","volume":"346","author":"LM Boyden","year":"2002","unstructured":"Boyden LM, Mao JH, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346:1513\u201321.","journal-title":"N Engl J Med"},{"key":"229_CR17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/joim.12368","volume":"277","author":"UH Lerner","year":"2015","unstructured":"Lerner UH, Ohlsson C. The WNT system: background and its role in bone. J Intern Med. 2015;277:630\u201349.","journal-title":"J Intern Med"},{"key":"229_CR18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.2249","volume":"44","author":"K Estrada","year":"2012","unstructured":"Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012;44:491\u2013501.","journal-title":"Nat Genet"},{"key":"229_CR19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","volume":"10","author":"W Balemans","year":"2001","unstructured":"Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537\u201343.","journal-title":"Hum Mol Genet"},{"key":"229_CR20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","volume":"39","author":"W Balemans","year":"2002","unstructured":"Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39:91\u20137.","journal-title":"J Med Genet"},{"key":"229_CR21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.10401","volume":"110","author":"K Staehling-Hampton","year":"2002","unstructured":"Staehling-Hampton K, Proll S, Paeper BW, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002;110:144\u201352.","journal-title":"Am J Med Genet"},{"key":"229_CR22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00439-011-0947-3","volume":"129","author":"SJ Kim","year":"2011","unstructured":"Kim SJ, Bieganski T, Sohn YB, et al. Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia. Hum Genet. 2011;129:497\u2013502.","journal-title":"Hum Genet"},{"key":"229_CR23","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1210\/jc.2005-1235","volume":"90","author":"JC Gardner","year":"2005","unstructured":"Gardner JC, van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab. 2005;90:6392\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"229_CR24","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/jbmr.474","volume":"26","author":"AH Lierop van","year":"2011","unstructured":"van Lierop AH, Hamdy NAT, Hamersma H, et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res. 2011;26:2804\u201311.","journal-title":"J Bone Miner Res"},{"key":"229_CR25","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","volume":"23","author":"X Li","year":"2008","unstructured":"Li X, Ominsky MS, Niu Q-T, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23:860\u20139.","journal-title":"J Bone Miner Res"},{"key":"229_CR26","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","volume":"24","author":"XD Li","year":"2009","unstructured":"Li XD, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24:578\u201388.","journal-title":"J Bone Miner Res"},{"key":"229_CR27","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","volume":"25","author":"MS Ominsky","year":"2010","unstructured":"Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25:948\u201359.","journal-title":"J Bone Miner Res"},{"key":"229_CR28","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/jbmr.3036","volume":"32","author":"MS Ominsky","year":"2016","unstructured":"Ominsky MS, Boyd SK, Varela A, et al. Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys. J Bone Miner Res. 2016;32:788\u2013801.","journal-title":"J Bone Miner Res"},{"key":"229_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bone.2016.10.019","volume":"96","author":"MS Ominsky","year":"2017","unstructured":"Ominsky MS, Boyce RW, Li X, et al. Effects of sclerostin antibodies in animal models of osteoporosis. Bone. 2017;96:63\u201375. doi:\n                        10.1016\/j.bone.2016.10.019\n                        \n                    .","journal-title":"Bone"},{"key":"229_CR30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19\u201326.","journal-title":"J Bone Miner Res"},{"key":"229_CR31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","volume":"54","author":"D Padhi","year":"2014","unstructured":"Padhi D, Allison M, Kivitz AJ, et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2014;54:168\u201378.","journal-title":"J Clin Pharmacol"},{"key":"229_CR32","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bone.2015.07.036","volume":"81","author":"C Graeff","year":"2015","unstructured":"Graeff C, Campbell GM, Pe\u00f1a J, et al. Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis. Bone. 2015;81:364\u20139.","journal-title":"Bone"},{"key":"229_CR33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412\u201320.","journal-title":"N Engl J Med"},{"key":"229_CR34","first-page":"S53","volume":"29","author":"MR McClung","year":"2014","unstructured":"McClung MR, Chines A, Brown JP, et al. Effects of 2 years of treatment with romosozumab followed by 1 year ofdenosumab or placebo in postmenopausal women with low bone mineral density. J Bone Miner Res. 2014;29:S53.","journal-title":"J Bone Miner Res"},{"key":"229_CR35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jbmr.2932","volume":"32","author":"HK Genant","year":"2017","unstructured":"Genant HK, Engelke K, Bolognese MA, et al. Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res. 2017;32:181\u20137.","journal-title":"J Bone Miner Res"},{"key":"229_CR36","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532\u201343.","journal-title":"N Engl J Med"},{"key":"229_CR37","unstructured":"Amgen. Clinial Trials. Clinical trial summary: 20110142. Study to determine the efficacy and safety of romosozumab in the treatment of postmenopausal women with osteoporosis. Amgen: March 2017. \n                        http:\/\/www.amgentrials.com\/amgen\/trialsummary.aspx?studyid=20110142\n                        \n                    ."},{"key":"229_CR38","unstructured":"Amgen. Results from phase 3 BRIDGE study show romosozumab significantly increases bone mineral density in men with osteoporois [media release]. Thousand Oaks, CA: Amgen; 12 November 2016. \n                        http:\/\/wwwext.amgen.com\/media\/news-releases\/2016\/11\/results-from-phase-3-bridge-study-show-romosozumab-significantly-increases-bone-mineral-density-in-men-with-osteoporosis\/\n                        \n                    ."},{"key":"229_CR39","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","volume":"29","author":"J McColm","year":"2014","unstructured":"McColm J, Hu L, Womack T, et al. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res. 2014;29:935\u201343.","journal-title":"J Bone Miner Res"},{"key":"229_CR40","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","volume":"30","author":"RR Recker","year":"2015","unstructured":"Recker RR, Benson CT, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30:216\u201324.","journal-title":"J Bone Miner Res"},{"key":"229_CR41","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.2489","volume":"30","author":"CP Recknor","year":"2015","unstructured":"Recknor CP, Recker RR, Benson CT, et al. The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30:1717\u201325.","journal-title":"J Bone Miner Res"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-017-0229-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0229-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0229-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T02:44:09Z","timestamp":1502160249000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-017-0229-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["229"],"URL":"https:\/\/doi.org\/10.1007\/s40259-017-0229-2","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,25]]}}}